This is a past event. Registration is closed.
View other
DIA China
events.
Log In
EN
中文
English
OVERVIEW
Agenda
Registration
Speakers
Exhibition and Hosting
CALL FOR POSTER
Venue and Hotel
Download
Sponsors and Partners
More
OVERVIEW
Agenda
Registration
Speakers
Exhibition and Hosting
CALL FOR POSTER
Venue and Hotel
Download
Sponsors and Partners
Speakers
讲者简介(
点击此处
下载)
徐宁(大会指导委员会成员)
再鼎制药执行副总裁,临床研发及法规事务负责人
Opening Plenary Session
www.firstnamelastname.nl
@firstname
薛斌(大会指导委员会成员)
中国食品药品国际交流中心主任
Opening Plenary Session
www.firstnamelastname.nl
@firstname
胡蓓(大会指导委员会成员)
北京协和医院临床药理中心l期临床研究室
Session 0707 Pharmacometrics in Early Stage of Clinical Development
Session 0901 Strategy of Clinical Development
Session 0905 How to Improve Development Efficiency and Save Clinical Resource
www.firstnamelastname.nl
@firstname
吕玉真(大会指导委员会成员)
罗氏(中国)投资有限公司亚太区法规部门负责人
www.firstnamelastname.nl
@firstname
邵颖(大会指导委员会成员)
上海复星医药集团副总裁兼研发中心主任
Session 1106
www.firstnamelastname.nl
@firstname
苏岭(大会指导委员会成员)
沈阳药科大学教授;药品监管科学研究所所长;礼来亚洲基金风险合伙人
Session 0105 China Regulatory Reform to Build A Productive Ecosystem
www.firstnamelastname.nl
@firstname
王劲松(大会指导委员会成员)
和铂医药首席执行官
www.firstnamelastname.nl
@firstname
朱立红(大会指导委员会成员)
DIA中国区董事总经理
Opening Plenary Session
Session 1101
Session 1106
www.firstnamelastname.nl
@firstname
曹莉莉(大会组织委员会成员)
国家食品药品监督管理总局中国食品药品国际交流中心(CCFDIE)对外合作处处长
www.firstnamelastname.nl
@firstname
曹晓春(大会组织委员会成员)
泰格医药科技股份公司执行副总裁兼董事会秘书
www.firstnamelastname.nl
@firstname
谷成明(大会组织委员会成员)
辉瑞中国医学部副总裁
www.firstnamelastname.nl
@firstname
郭翔(大会组织委员会成员)
默沙东研发(中国)有限公司生物统计高级总监
Session 0501 Quantitative Science and New Regulatory Guidance
Session 0506 Accelerate Drug Development with Innovative Statistical Method
www.firstnamelastname.nl
@firstname
黄钦(大会组织委员会成员)
国家食品药品监督管理总局药品审评中心
www.firstnamelastname.nl
@firstname
梁冰(大会组织委员会成员)
辉瑞全球安全及药政事务部安全监测及风险管理 高级总监
www.firstnamelastname.nl
@firstname
蔺亚萌(大会组织委员会成员)
罗氏(中国)投资有限公司CMC政策法规资深经理
www.firstnamelastname.nl
@firstname
刘晓曦(大会组织委员会成员)
和铂生物医药副总裁早期研发与科学运营
www.firstnamelastname.nl
@firstname
宁志强(大会组织委员会成员)
深圳微芯生物科技有限责任公司研发执行副总裁
Session 0401 Target Discovery & Preclincal Development
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
曲鹏(大会组织委员会成员)
辉瑞(中国)研究开发有限公司统计部高级总监
www.firstnamelastname.nl
@firstname
孙华龙(大会组织委员会成员)
美达临床数据技术有限公司总经理
www.firstnamelastname.nl
@firstname
王莉(大会组织委员会成员)
礼来中国首席医学官,药物研发及医学事物中心副总裁
Session 0601 The Evolvement of Medical Affairs in New Era
Session 0608 Career Development of Medical Affairs Personnel: Face to Face with the Senior Leaders
www.firstnamelastname.nl
@firstname
王敏(大会组织委员会成员)
启明创维创业投资管理(上海)有限公司投资合伙人
Session 0906 Panel Discussion
www.firstnamelastname.nl
@firstname
闫小军(大会组织委员会成员)
百济神州高级副总裁及药政事务部负责人
Session 0106 Consideration and Case Study of Expediting Development and Review of New Drugs
www.firstnamelastname.nl
@firstname
杨青(大会组织委员会成员)
药明康德执行副总裁及首席运营官
www.firstnamelastname.nl
@firstname
张海洲(大会组织委员会成员)
先声药业临床前研发负责人
www.firstnamelastname.nl
@firstname
赵大尧(大会组织委员会成员)
辉瑞中国副总裁中国药物开发部负责人
www.firstnamelastname.nl
@firstname
冯平辉(壁报评审委员)
南加州大学分子微生物学和免疫学系
www.firstnamelastname.nl
@firstname
李正卿(壁报评审委员)
默沙东全球副总裁中国研发中心总经理
www.firstnamelastname.nl
@firstname
曾革非(壁报评审委员)
默沙东研发(中国)有限公司战略计划及信息学总监
www.firstnamelastname.nl
@firstname
宁光
上海交通大学医学院附属瑞金医院副院长
Opening Plenary Session
www.firstnamelastname.nl
@firstname
李元念
江苏豪森药业集团有限公司高级副总裁;上海翰森医药生物有限公司执行总经理
GMP, CMC
www.firstnamelastname.nl
@firstname
刘萍
辉瑞中国临床药理部负责人
GMP, CMC
www.firstnamelastname.nl
@firstname
雷继峰
上海安必生制药技术有限公司创始人兼首席执行官
GMP, CMC
www.firstnamelastname.nl
@firstname
Dale CONNER
美国FDA药品评价与研究中心(CDER)生物等效性办公室仿制药办公室主任
GMP, CMC
www.firstnamelastname.nl
@firstname
Alexander HÖNEL
The Inspectors Network Consulting and Training Services质量专家
GMP, CMC
Session 0301 Progress and Impact of New Regulations on Clinical Research
www.firstnamelastname.nl
@firstname
李雪宁
中山医院
GMP, CMC
www.firstnamelastname.nl
@firstname
谢雨礼
上海药明康德新药开发有限公司CMC办公室主任
GMP, CMC
Session 0401 Target Discovery & Preclincal Development
www.firstnamelastname.nl
@firstname
磨筱垚
北京人和广通资讯有限公司药物安全顾问
Pharmacovigilance and Risk Management from Clinical Trials
www.firstnamelastname.nl
@firstname
赵子贤
阿斯利康美国药物安全监测部门主管医学执行总监
Pharmacovigilance and Risk Management from Clinical Trials
www.firstnamelastname.nl
@firstname
陈小祥
勃林格殷格翰副总裁,亚洲区医学管理
Statistics for Medical Affairs
www.firstnamelastname.nl
@firstname
郭翔
默沙东研发(中国)有限公司生物统计高级总监
Statistics for Medical Affairs
www.firstnamelastname.nl
@firstname
李智
勃林格殷格翰医学事务I部总监
Statistics for Medical Affairs
Session 0607 Optimizing the Product Life Cycle
www.firstnamelastname.nl
@firstname
梁立平
默沙东(中国)投资有限公司医学事务部医学信息副总监
www.firstnamelastname.nl
@firstname
邱婧君
拜耳医药保健有限公司数据科学与分析高级统计师
Statistics for Medical Affairs
www.firstnamelastname.nl
@firstname
卫芳
默沙东高级医学事务总监
Statistics for Medical Affairs
Session 0607 Optimizing the Product Life Cycle
www.firstnamelastname.nl
@firstname
孙华龙
美达临床数据技术公司总经理
Data Process Review
www.firstnamelastname.nl
@firstname
颜崇超
江苏恒瑞医药股份有限公司数据管理部资深总监
Data Process Review
www.firstnamelastname.nl
@firstname
浦迪
精鼎医药研究开发(上海)有限公司临床数据管理部经理
Data Process Review
www.firstnamelastname.nl
@firstname
代囡
美达临床数据技术公司临床数据管理部经理
Data Process Review
www.firstnamelastname.nl
@firstname
秦晓岺
国家食品药品监督管理总局国际合作司副司长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
袁林
国家食品药品监督管理总局国际合作司司长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Theresa MULLIN
美国FDA药品评价和研究中心(CDER)战略规划办公室主任
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
安田尚之
日本药物医疗器械监督局国际项目办公室主任
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Barbara KUNZ
DIA 全球首席执行官
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
李自力
美国FDA药品评价和研究中心(CDER)仿制药办公室全球事务副主任
CFDA/DIA Joint Workshop on ICH
Session 0102 Where Does China:Stand in the Middle of ICH Updates
Session 0108 To Accelerate Regulatory Approval of and Patient’s Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice
www.firstnamelastname.nl
@firstname
斋腾宏畅
日本第一三共制药癌症临床开发部长;日本制药工业协会ICH委员会副委员长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Vibeke BJERREGAARD
丹麦诺和诺德法规政策高级注册事务经理;ICH E17 专家工作组成员
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Wassim NASHABEH
Genentech(罗氏集团)技术注册法规和策略全球负责人;ICH专家工作组质量课题 Q11、Q3D、Q12成员
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
王翔宇
国家食品药品监督管理总局国际合作司国际组织处处长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
舒融
中国食品药品国际交流中心副主任
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
宋瑞霖
中国医药创新促进会执行会长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
王磊
阿斯利康公司全球执行副总裁,亚太区及中国总裁
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
李正卿
默沙东全球副总裁中国研发中心总经理
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Kerry L BLANCHARD
礼来中国医学研发和外部创新高级副总裁
www.firstnamelastname.nl
@firstname
苏岭
沈阳药科大学教授,药品监管科学研究所所长;礼来亚洲基金风险合伙人
Opening Plenary Session
www.firstnamelastname.nl
@firstname
华杰鸿
欧盟驻华使团公使衔参赞
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
郑晓瑛
北京大学人口研究所/世界卫生组织生殖健康和人口科学合作中心所长
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
杨悦
沈阳药科大学国际食品药品政策与法律研究中心主任
CFDA/DIA Joint Workshop on ICH
Session 0105 China Regulatory Reform to Build A Productive Ecosystem
www.firstnamelastname.nl
@firstname
许铭
中国医药保健品进出口商会副会长
www.firstnamelastname.nl
@firstname
宋华琳
南开大学法学院教授
CFDA/DIA Joint Workshop on ICH
www.firstnamelastname.nl
@firstname
Barbara Lopez KUNZ
DIA全球执行理事长
www.firstnamelastname.nl
@firstname
陆舜
上海胸科医院肺癌中心主任
Opening Plenary Session
www.firstnamelastname.nl
@firstname
江宁军
基石医药首席执行官
Opening Plenary Session
www.firstnamelastname.nl
@firstname
杨佩蓉
中国罕见病发展中心(CORD)国际事务部总监
Opening Plenary Session
www.firstnamelastname.nl
@firstname
韩凤云
强生亚太制药部全球法规事务亚太区法规政策事务负责人、高级总监
www.firstnamelastname.nl
@firstname
Edward COX
美国FDA药品评价和研究中心(CDER)新药办公室抗菌产品办公室主任
Session 0101 Worldwide Regulatory Science Emerging Focus
www.firstnamelastname.nl
@firstname
Adam HACKER
强生公司制药部全球法规事务部疫苗及科学创新项目负责人,副总裁
Session 0101 Worldwide Regulatory Science Emerging Focus
www.firstnamelastname.nl
@firstname
胡劲捷
Biologics Consulting Group高级顾问;FDA同仁会国际部主席;前美国FDA/CBER血液研究和评价办公室;高级审评官员
Session 0101 Worldwide Regulatory Science Emerging Focus
www.firstnamelastname.nl
@firstname
张象麟
沈阳药科大学亦弘商学院
Session 0102 Where Does China:Stand in the Middle of ICH Updates
www.firstnamelastname.nl
@firstname
Florence HOUN
美国新基制药全球法规事务副总裁;美国FDA同仁会会员,前主席
Session 0102 Where Does China:Stand in the Middle of ICH Updates
www.firstnamelastname.nl
@firstname
李寅
科睿唯安产品与解决方案顾问
Session 0105 China Regulatory Reform to Build A Productive Ecosystem
www.firstnamelastname.nl
@firstname
闫小军
百济神州高级副总裁及药政事务部负责人
www.firstnamelastname.nl
@firstname
王雅敏
德国独立顾问
Session 0106 Consideration and Case Study of Expediting Development and Review of New Drugs
www.firstnamelastname.nl
@firstname
Mark Goldberger
美国FDA同仁会国际部成员;前美国FDA药品评价和研究中心(CDER);新药办公室抗菌产品办公室主任
Session 0106 Consideration and Case Study of Expediting Development and Review of New Drugs
www.firstnamelastname.nl
@firstname
邵颖
上海复星医药集团副总裁兼研发中心主任
Session 0107 Products Regulatory Supervision and Quality Control
www.firstnamelastname.nl
@firstname
Lane CHRISTENSEN
美国FDA中国办公室助理主任
Session 0107 Products Regulatory Supervision and Quality Control
www.firstnamelastname.nl
@firstname
张庆
诺和诺德公司全球质量部门副总裁
Session 0107 Products Regulatory Supervision and Quality Control
www.firstnamelastname.nl
@firstname
韩凤云
强生亚太制药部全球法规事务亚太区法规政策事务负责人高级总监
Session 0101 Worldwide Regulatory Science Emerging Focus
Session 0108 To Accelerate Regulatory Approval of and Patient’s Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice
www.firstnamelastname.nl
@firstname
黄琴喨
APEC 法规事务指导委员会,良好注册管理卓越中心专家
Session 0108 To Accelerate Regulatory Approval of and Patient’s Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice
www.firstnamelastname.nl
@firstname
Shinji HATAKEYAMA
卫材日本药物开发中心,日本/亚洲法规事务和临床运营部总监;APEC 法规事务指导委员会,良好注册管理卓越中心专家
www.firstnamelastname.nl
@firstname
蒲绘华
罗氏中国注册事务副总监
Session 0108 To Accelerate Regulatory Approval of and Patient’s Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice
www.firstnamelastname.nl
@firstname
陈华
西安杨森公司药物研发质量和合规部亚太区及中国研发中心质量保证总监
Session 0301 Progress and Impact of New Regulations on Clinical Research
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
Peter SCHIEMANN
Widler & Schiemann公司管理合伙人
Session 0301 Progress and Impact of New Regulations on Clinical Research
www.firstnamelastname.nl
@firstname
沈一峰
上海市精神卫生中心机构办公室主任
Session 0301 Progress and Impact of New Regulations on Clinical Research
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
周立萍
默沙东研发(中国)有限公司亚太区质量保证总监
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
黎婉珊
默沙东(研发)有限公司全球临床数据管理中心亚太区总监
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
孙晔
中国百时美施贵宝质量保证亚太区
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
王方敏
上海药品审评核查中心副主任
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
汪秀琴
江苏省人民医院南京医科大学第一附属医院伦理总监、伦理委员会副主任委员、科技处副处长
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
夏文璐
QuintilesIMS副总裁
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
阎昭
天津医科大学肿瘤医院药物临床试验机构办公室主任
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
李万波
拜耳临床药理学亚太部/普药临床药理学运作总监-中国
Session 0305 High Quality of Clinical Research Comes from Risk-Management Driven Project Management System
www.firstnamelastname.nl
@firstname
田中华
强生中国/杨森制药/临床研究战略运营及临床研究管理(抗感染领域)总监
Session 0305 High Quality of Clinical Research Comes from Risk-Management Driven Project Management System
www.firstnamelastname.nl
@firstname
白桦
中国医学科学院北京协和医院临床药理研究中心
Session 0305 High Quality of Clinical Research Comes from Risk-Management Driven Project Management System
www.firstnamelastname.nl
@firstname
陈睿
赛诺菲高级临床研究运营经理
Session 0305 High Quality of Clinical Research Comes from Risk-Management Driven Project Management System
www.firstnamelastname.nl
@firstname
许文宬
上海康德弘翼医学临床研究有限公司项目发展整合管理总监
Session 0305 High Quality of Clinical Research Comes from Risk-Management Driven Project Management System
www.firstnamelastname.nl
@firstname
刘佳
杭州泰格海外业务管理副总裁
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
蒋皓媛
江西青峰药业有限公司上海分公司高级副总裁,首席医学官
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
李树婷
原中国医学科学院肿瘤医院药物临床研究中心GCP中心办公室副主任,伦理委员会秘书
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
张艳
Q2 Solutions 亚太区副总裁兼总经理
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
吴龑
和记黄埔医药临床运营负责人,执行总监
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
刘寒松
科文斯中心实验室服务中国总经理
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
王皓
施贵宝中国临床运营高级总监
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
徐列东
科文斯临床研究部中国区负责人
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
周玉梅
赛诺菲科学与临床采购部负责人(中韩澳新)负责人
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
邓亚中
北京信立达医药科技有限公司总经理
Session 0307 How to Ensure the Data Integrity in Clinical Trials
www.firstnamelastname.nl
@firstname
李锡明
石药集团副总裁,首席医学官
Session 0307 How to Ensure the Data Integrity in Clinical Trials
www.firstnamelastname.nl
@firstname
顾哲明
万略医药科技有限公司总经理
Session 0307 How to Ensure the Data Integrity in Clinical Trials
www.firstnamelastname.nl
@firstname
张玥
博纳西亚医药科技有限公司数据统计分公司总裁
Session 0307 How to Ensure the Data Integrity in Clinical Trials
www.firstnamelastname.nl
@firstname
孙华龙
美达临床数据技术有限公司总经理
Session 0308 Apply New Technology/Method to Improve Data Quality in Clinical Trial
www.firstnamelastname.nl
@firstname
包文俊
美国SAS软件研究所JMP生命科学部首席科学家兼资深研发经理
Session 0308 Apply New Technology/Method to Improve Data Quality in Clinical Trial
www.firstnamelastname.nl
@firstname
Eric HERBEL
Integrated Clinical Systems, Inc.总经理
Session 0308 Apply New Technology/Method to Improve Data Quality in Clinical Trial
www.firstnamelastname.nl
@firstname
卢宝蓝
默沙东研发(中国)有限公司全球临床数据管理中心副总监
Session 0308 Apply New Technology/Method to Improve Data Quality in Clinical Trial
www.firstnamelastname.nl
@firstname
鲁先平
深圳微芯生物科技有限公司总裁兼首席科学官
Session 0401 Target Discovery & Preclincal Development
Session 1106
Session 1207 Rare Disease, Unsatisfied Market Demand
www.firstnamelastname.nl
@firstname
谢雨礼
上海药明康德新药开发有限公司CMC办公室主任
www.firstnamelastname.nl
@firstname
沈月雷
北京百奥赛图基因生物技术有限公司董事长兼首席执行官
Session 0401 Target Discovery & Preclincal Development
www.firstnamelastname.nl
@firstname
刘晓曦
和铂生物医药副总裁,早期研发与科学运营
Session 0402 Early Stage Clinical Development
www.firstnamelastname.nl
@firstname
汪裕
北京博纳西亚医药科技有限公司首席科学官
Session 0402 Early Stage Clinical Development
www.firstnamelastname.nl
@firstname
Mithat GöNEN
美国纪念斯隆-凯特琳癌症中心生物统计主管
Session 0402 Early Stage Clinical Development
www.firstnamelastname.nl
@firstname
黑永疆
美国安博生物公司首席医学官
Session 0405 Late Stage Clinical Development
www.firstnamelastname.nl
@firstname
申华琼
杨森制药中国研发与医学事务部副总裁,临床研发负责人
Session 0405 Late Stage Clinical Development
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
邹建军
江苏恒瑞医药股份有限公司临床研究与开发副总裁
Session 0405 Late Stage Clinical Development
www.firstnamelastname.nl
@firstname
王丽霞
美国CTI生物公司生物统计、医药经济及转归研究部高级副总裁
Session 0405 Late Stage Clinical Development
www.firstnamelastname.nl
@firstname
董晨
清华大学医学院院长
Session 0406 Immuno Oncology
www.firstnamelastname.nl
@firstname
张连山
恒瑞医药副总经理
Session 0406 Immuno Oncology
www.firstnamelastname.nl
@firstname
Forrest ANTHONY
昆泰全球肿瘤卓越研究中心高级总监
Session 0406 Immuno Oncology
www.firstnamelastname.nl
@firstname
江泽飞
军事医学科学院附属医院(北京307医院)乳癌科主任
Session 0407 Precision Medicine
www.firstnamelastname.nl
@firstname
刘颢
燃石医学首席医学官
Session 0407 Precision Medicine
www.firstnamelastname.nl
@firstname
胡劲捷
Biologics Consulting Group高级顾问;FDA同仁会会员;前美国FDA/CBER血液研究和评价办公室,高级审评官员
Session 0407 Precision Medicine
www.firstnamelastname.nl
@firstname
邓婷
阿斯利康中国法规负责人,副总裁
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
朱林
恒瑞医药中国注册事务负责人,总监
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
张磊
西安杨森制药有限公司中国注册事务负责人,高级总监
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
陈之健
阿斯利康公司全球药物开发高级副总裁,中国新药开发部总裁
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
牟骅
先声药业研发总裁兼首席科学家
Session 0408 Regulatory & World-wide Development
www.firstnamelastname.nl
@firstname
刘映雪
辉瑞(中国)研究开发有限公司统计副总监
Session 0501 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
蒋志伟
默沙东研发(中国)有限公司生物统计与科学决策部门高级统计师
Session 0501 Quantitative Science and New Regulatory Guidance
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
王勇
精鼎医药亚太区生物统计高级总监
Session 0501 Quantitative Science and New Regulatory Guidance
Session 0505 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
陈峰
南京医科大学公共卫生学院院长中国卫生统计学会统计理论与方法专业委员会主任委员;中国临床试验生物统计学组(CCTS)组长
Session 0501 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
李芳
罗氏亚太区生物统计总监
Session 0501 Quantitative Science and New Regulatory Guidance
Session 0506 Accelerate Drug Development with Innovative Statistical Method
www.firstnamelastname.nl
@firstname
汪涛
江苏恒瑞医药肿瘤临床研发部生物统计与编程组负责人,总监
Session 0501 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
邓亚中
北京信立达医药科技有限公司总经理
Session 0502 CDISC/EDC
Session 0505-2 Clinical Data – Regulatory Requirement
www.firstnamelastname.nl
@firstname
夏结来
第四军医大学卫生统计学教研室
Session 0501 Quantitative Science and New Regulatory Guidance
Session 0505-2 Clinical Data – Regulatory Requirement
www.firstnamelastname.nl
@firstname
张子豹
缔脉生物医药科技(上海)有限公司生物统计与编程部高级总监
Session 0502 CDISC/EDC
www.firstnamelastname.nl
@firstname
Jim STREETER
甲骨文健康科学全球生命科学产品战略副总裁
Session 0502 CDISC/EDC
www.firstnamelastname.nl
@firstname
虞海平
缔脉生物医药科技(上海)有限公司临床数据管理技术运营负责人
Session 0502 CDISC/EDC
www.firstnamelastname.nl
@firstname
韩立
罗氏制药生物统计学肿瘤晚期临床数据管理经理
Session 0502 CDISC/EDC
www.firstnamelastname.nl
@firstname
马东
嘉兴太美医疗科技有限公司临床研究事业部副总裁
Session 0502 CDISC/EDC
Session 1306 MobileMD System White Paper Showcase
www.firstnamelastname.nl
@firstname
戴鲁燕
勃林格殷格翰亚太区生物统计与数据科学部大中华区生物统计负责人,总监
Session 0505 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
易秉明
葛兰素史克(中国)统计流行病学,数据管理部门负责人
Session 0505 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
Lucy FRITH
葛兰素史克(中国)呼吸系统临床统计总监
Session 0505 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
颜崇超
江苏恒瑞数据科学中心负责人
Session 0505-2 Clinical Data – Regulatory Requirement
www.firstnamelastname.nl
@firstname
付海军
上海凯锐斯生物科技有限公司总经理
Session 0505-2 Clinical Data – Regulatory Requirement
www.firstnamelastname.nl
@firstname
陈聪
默沙东早期肿瘤统计总监
Session 0506 Accelerate Drug Development with Innovative Statistical Method
www.firstnamelastname.nl
@firstname
朱连升
诺华制药全球药物开发临床开发与分析学生物统计组负责人
Session 0507 Statistical Considerations in Clinical Development
www.firstnamelastname.nl
@firstname
廖珊妹
辉瑞中国生物统计副总监
Session 0507 Statistical Considerations in Clinical Development
www.firstnamelastname.nl
@firstname
MaryAnn Morgan-COX
美国礼来统计与高级分析学首席研究员
Session 0507 Statistical Considerations in Clinical Development
www.firstnamelastname.nl
@firstname
祝琦
诺华制药生物统计首席生物统计师
Session 0507 Statistical Considerations in Clinical Development
www.firstnamelastname.nl
@firstname
殷悦
罗氏(中国)投资有限公司生物统计副总监
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
王钧源
默克雪兰诺全球生物统计,流行病学和医学写作部中国负责人
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
陈文锋
默克雪兰诺全球生物统计,流行病学和医学写作部
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
高岩菲
默克雪兰诺全球生物统计,流行病学和医学写作部
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
唐雄文
罗氏(中国)投资有限公司统计科学家
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
俞章盛
上海交通大学-耶鲁大学, 联合生物统计学中心副主任
Session 0508 New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials
www.firstnamelastname.nl
@firstname
Salvador GARCIA DE QUEVEDO
礼来制药医学事务全球副总裁
Session 0601 The Evolvement of Medical Affairs in New Era
www.firstnamelastname.nl
@firstname
张芳宁
麦肯锡大中华区上海办公室全球董事合伙人
Session 0601 The Evolvement of Medical Affairs in New Era
www.firstnamelastname.nl
@firstname
宁毅
GSK Senior fellow of the Council of Fellows,流行病学负责人
Session 0602 Real-world Evidence and Healthoutcome
www.firstnamelastname.nl
@firstname
曹海俊
礼来中国卫生经济学团队负责人
Session 0602 Real-world Evidence and Healthoutcome
www.firstnamelastname.nl
@firstname
陶立波
中山大学医药经济研究所研究员
Session 0602 Real-world Evidence and Healthoutcome
www.firstnamelastname.nl
@firstname
康志清
阿斯利康医学事务部中国与香港医学事务副总裁
Session 0605 Multi-channels Medical Communication
www.firstnamelastname.nl
@firstname
毛京梅
默克雪兰诺中国研发中心医学事务部负责人
Session 0605 Multi-channels Medical Communication
www.firstnamelastname.nl
@firstname
李健
阿斯利康医学事务部医学信息和合规部门医学总监
Session 0605 Multi-channels Medical Communication
www.firstnamelastname.nl
@firstname
周苏
博福-益普生专科产品中国/辅助体外生殖全球医学事务部负责人
Session 0605 Multi-channels Medical Communication
www.firstnamelastname.nl
@firstname
贺李敬
诺华中国医学事务副总裁
Session 0606 “Medical Driven” in Cross Functions’ Eyes
Session 0608 Career Development of Medical Affairs Personnel: Face to Face with the Senior Leaders
www.firstnamelastname.nl
@firstname
任腾
葛兰素史克亚洲、中东及非洲伦理与合规负责人
Session 0606 “Medical Driven” in Cross Functions’ Eyes
www.firstnamelastname.nl
@firstname
张方直
罗氏中国医学事务副总裁
Session 0607 Optimizing the Product Life Cycle
Session 0608 Career Development of Medical Affairs Personnel: Face to Face with the Senior Leaders
www.firstnamelastname.nl
@firstname
Cindy ZHU
罗氏医学科学--肿瘤副总监
www.firstnamelastname.nl
@firstname
贺李敬
诺华中国医学事务副总裁
www.firstnamelastname.nl
@firstname
王小玲
赛诺菲中国研发临床科学运营部临床档案负责人
Session 0607-2 Development of Clinical Documents for Regulatory Submission to Meet the CFDA Requirements and to Proactively Address CFDA Inspection Points
www.firstnamelastname.nl
@firstname
栗菲
礼来中国医学部科学沟通高级经理
Session 0607-2 Development of Clinical Documents for Regulatory Submission to Meet the CFDA Requirements and to Proactively Address CFDA Inspection Points
www.firstnamelastname.nl
@firstname
冀呈雪
波士顿科学医学与法规事务部临床评价经理
Session 0607-2 Development of Clinical Documents for Regulatory Submission to Meet the CFDA Requirements and to Proactively Address CFDA Inspection Points
www.firstnamelastname.nl
@firstname
汪海丹
上海康德弘翼医学临床研究有限公司医学主任
Session 0607-2 Development of Clinical Documents for Regulatory Submission to Meet the CFDA Requirements and to Proactively Address CFDA Inspection Points
www.firstnamelastname.nl
@firstname
Andrea HENNIG
拜耳制药全科医学医学写作负责人
Session 0608-2 Cross-Functional Collaboration to Prepare High Quality Clinical Documents to Support IND, Pre-NDA And NDA Submissions
www.firstnamelastname.nl
@firstname
张磊
精鼎医药医学报告撰写部副经理
Session 0608-2 Cross-Functional Collaboration to Prepare High Quality Clinical Documents to Support IND, Pre-NDA And NDA Submissions
www.firstnamelastname.nl
@firstname
王楠
拜耳制药医学撰写(普药)中国及芬兰地区负责人
Session 0608-2 Cross-Functional Collaboration to Prepare High Quality Clinical Documents to Support IND, Pre-NDA And NDA Submissions
www.firstnamelastname.nl
@firstname
郑凝
赛诺菲临床文件撰写及管理部高级医学写作
Session 0608-2 Cross-Functional Collaboration to Prepare High Quality Clinical Documents to Support IND, Pre-NDA And NDA Submissions
www.firstnamelastname.nl
@firstname
杨泓
罗氏(中国)投资有限公司注册总监
Session 0701 Clinical Trial Design of Biosimilar Part I
Session 0702 Clinical Trial Design of Biosimilar Part II
www.firstnamelastname.nl
@firstname
王俭
加拿大卫生部生物与基因治疗局,放射与生物治疗药物评审中心,血液与肿瘤临床评价部主管
Session 0701 Clinical Trial Design of Biosimilar Part I
Session 0705 Recent Trends in the Regulation of Biopharmaceutical Products
www.firstnamelastname.nl
@firstname
汲萍
生物类似物开发的临床考量:生物类似物单克隆抗体在欧盟审评的案例分享
Session 0701 Clinical Trial Design of Biosimilar Part I
www.firstnamelastname.nl
@firstname
曹军宁
复旦大学附属肿瘤医院,肿瘤内科
Session 0702 Clinical Trial Design of Biosimilar Part II
www.firstnamelastname.nl
@firstname
蔺亚萌
罗氏(中国)投资有限公司CMC政策法规资深经理
Session 0705 Recent Trends in the Regulation of Biopharmaceutical Products
www.firstnamelastname.nl
@firstname
张海洲
先声药业临床前研发负责人
Session 0708 Development of Cell Therapy and Regulatory Considerations
www.firstnamelastname.nl
@firstname
Chris CHEN
WuXi Biologics(美国)首席执行官
www.firstnamelastname.nl
@firstname
张华
上海药品审评核查中心副主任
Session 0706 Regulating Biologics under MAH Pilot Program
www.firstnamelastname.nl
@firstname
张庆
诺和诺德公司全球质量部门副总裁
Session 0706 Regulating Biologics under MAH Pilot Program
www.firstnamelastname.nl
@firstname
陈宇
罗氏(中国)投资有限公司上海全球研发中心注册总监
Session 0707 Pharmacometrics in Early Stage of Clinical Development
www.firstnamelastname.nl
@firstname
严瑾
美国罗氏Genentech建模与模拟全球负责人与神经科学临床药理组组长,副总监,科学家
Session 0707 Pharmacometrics in Early Stage of Clinical Development
www.firstnamelastname.nl
@firstname
赵阳兵
美国宾夕法尼亚大学病理和实验医学系
Session 0708 Development of Cell Therapy and Regulatory Considerations
www.firstnamelastname.nl
@firstname
Yow-Ming Chen WANG
美国FDA药品评价和研究中心(CDER)转化医学办公室,临床药理学办公室,临床药理三部生物药品组组长
Session 0708 Development of Cell Therapy and Regulatory Considerations
www.firstnamelastname.nl
@firstname
唐雪
辉瑞公司药物安全总监,区域药物安全负责人
Session 0801 Current Development in Pharmacovigilance – The Importance to Know What’s Going on
www.firstnamelastname.nl
@firstname
周凌云
赛诺菲中国及亚洲区安全负责人,总监
Session 0801 Current Development in Pharmacovigilance – The Importance to Know What’s Going on
www.firstnamelastname.nl
@firstname
周晓枫
美国辉瑞公司全球安全及药政事务部流行病学高级总监
Session 0801 Current Development in Pharmacovigilance – The Importance to Know What’s Going on
www.firstnamelastname.nl
@firstname
Jae-Gook SHIN
韩国仁济大学医学院药理学和临床药理学系教授,仁济大学釜山白医院
Session 0801 Current Development in Pharmacovigilance – The Importance to Know What’s Going on
www.firstnamelastname.nl
@firstname
Brian EDWARDS
NDA法规科学有限公司首席顾问及ISoP董事会成员
Session 0801 Current Development in Pharmacovigilance – The Importance to Know What’s Going on
www.firstnamelastname.nl
@firstname
张晓兰
辉瑞公司全球安全及药政事务部安全监测及风险管理总监
Session 0802 Established Products/Injectable Products Safety Monitoring and Risk Management
www.firstnamelastname.nl
@firstname
吴奕卿
新基制药药物安全风险管理与医学信息部资深经理
Session 0802 Established Products/Injectable Products Safety Monitoring and Risk Management
www.firstnamelastname.nl
@firstname
Ferdinando VEGNI
新基制药全球药物安全与风险管理副总裁
Session 0802 Established Products/Injectable Products Safety Monitoring and Risk Management
www.firstnamelastname.nl
@firstname
顾芸
辉瑞公司全球安全及药政事务部流行病学总监
Session 0802 Established Products/Injectable Products Safety Monitoring and Risk Management
www.firstnamelastname.nl
@firstname
张轶菁
拜耳中国药物警戒总监
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
林钦
默沙东药物警戒总监
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
纪立伟
北京医院药学部
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
王玉红
拜耳国际药品安全行政总监
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
Carol KORO
默沙东流行病学执行总监
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
史美深
罗氏产品发展药品安全风险管理部门亚太地区总监
Session 0806 Safety in Oncological Treatment
www.firstnamelastname.nl
@firstname
张巍峰
罗氏产品发展药品安全风险管理部门亚太地区药品安全科学家
Session 0806 Safety in Oncological Treatment
www.firstnamelastname.nl
@firstname
黄健
基因泰克全球药品安全风险管理早期临床开发部门资深药品安全科学负责人
Session 0806 Safety in Oncological Treatment
www.firstnamelastname.nl
@firstname
黄葵
辉瑞公司全球安全及药政事务部流行病学资深总监
Session 0806 Safety in Oncological Treatment
www.firstnamelastname.nl
@firstname
Stephen KNOWLES
礼来医学及获益风险管理部门资深总监
Session 0806 Safety in Oncological Treatment
www.firstnamelastname.nl
@firstname
陈力
华领医药技术(上海)有限公司董事长,总经理
Session 0901 Strategy of Clinical Development
www.firstnamelastname.nl
@firstname
Dennis BASHAW
美国FDA转化医学办公室,临床药理学办公室,临床药理三部部长
www.firstnamelastname.nl
@firstname
吴劲梓
歌礼药业浙江有限公司首席执行官
Session 0901 Strategy of Clinical Development
www.firstnamelastname.nl
@firstname
王敏
启明创维创业投资管理(上海)有限公司投资合伙人
Session 0902 Risk Mitigation in Early Drug Development
www.firstnamelastname.nl
@firstname
Adam COHEN
荷兰莱顿大学人类药物研究中心首席执行官
Session 0902 Risk Mitigation in Early Drug Development
www.firstnamelastname.nl
@firstname
JuAn WANG
医学博士礼来制药全球患者安全风险收益管理科学家
Session 0902 Risk Mitigation in Early Drug Development
www.firstnamelastname.nl
@firstname
Dennis BASHAW
美国FDA药品评价和研究中心(CDER)转化医学办公室,临床药理学办公室,临床药理三部部长
Session 0901 Strategy of Clinical Development
Session 0905 How to Improve Development Efficiency and Save Clinical Resource
www.firstnamelastname.nl
@firstname
John LAMBERT
精鼎医药副总裁,首席医学官
Session 0905 How to Improve Development Efficiency and Save Clinical Resource
www.firstnamelastname.nl
@firstname
Florence HOUN
美国新基制药全球法规事务副总裁;美国FDA同仁会会员
Session 1005 International Policy or Practices for Chinese Company
www.firstnamelastname.nl
@firstname
Mark Goldberger
美国FDA同仁会国际部成员;前美国FDA药品评价和研究中心(CDER);新药办公室抗菌产品办公室主任
Session 1005 International Policy or Practices for Chinese Company
www.firstnamelastname.nl
@firstname
陈琦琬
辉瑞全球CMC执行总监;美国FDA同仁会国际网络成员;前美国FDA新药审评质量评估部副部长
Session 1005 International Policy or Practices for Chinese Company
www.firstnamelastname.nl
@firstname
Jenny WU
药明康德
Session 1006 Licensing in/out in Drug Development
www.firstnamelastname.nl
@firstname
Yang CHEN
盛德国际律师事务所生命科学实践中国负责人,合伙人
Session 1006 Licensing in/out in Drug Development
www.firstnamelastname.nl
@firstname
邹建军
江苏恒瑞医药股份有限公司临床研究与开发副总裁
Session 1006 Licensing in/out in Drug Development
www.firstnamelastname.nl
@firstname
张志民
乐土投资集团跨境投资董事总经理
Session 1006 Licensing in/out in Drug Development
www.firstnamelastname.nl
@firstname
吕强
基石药业(苏州)有限公司运营负责人,高级副总裁
Session 1007 Start-up in Drug Development
www.firstnamelastname.nl
@firstname
杨建新
基石药业(苏州)有限公司首席医学官
Session 1007 Start-up in Drug Development
www.firstnamelastname.nl
@firstname
江磊
上海轶诺药业有限公司
Session 1007 Start-up in Drug Development
www.firstnamelastname.nl
@firstname
喻红平
上海和誉生物医药科技有限公司
www.firstnamelastname.nl
@firstname
刘冀
上海张江药谷公共服务平台有限公司副总经理;上海张江生物医药基地开发有限公司营销部部门经理
Session 1007 Start-up in Drug Development
www.firstnamelastname.nl
@firstname
郭彤
昆泰非洲亚洲地区生物统计负责人
Session 1101
www.firstnamelastname.nl
@firstname
Sebastien BOHN
Offering Manager, IBM Watson Heath Clinical Development;IBM沃森健康临床开发经理
Session 1101
www.firstnamelastname.nl
@firstname
谢国彤
IBM中国研究院认知医疗研究总监
Session 1101
www.firstnamelastname.nl
@firstname
阴忆青
上海中山医院上海中山医疗科技发展公司总经理,医院信息系统著名专家
Session 1101
www.firstnamelastname.nl
@firstname
彭逸天
药研社联合创始人
Session 1101
www.firstnamelastname.nl
@firstname
林亮
礼来亚洲基金合伙人
www.firstnamelastname.nl
@firstname
邵颖
上海复星医药集团副总裁,研发中心主任
www.firstnamelastname.nl
@firstname
闫慧
中国外商投资企业协会药品研制和开发行业委员会(RDPAC)科学与药政高级总监
Session 1106
www.firstnamelastname.nl
@firstname
张丹
方恩医药发展有限公司董事长兼总裁
www.firstnamelastname.nl
@firstname
许俊才
上海医药临床研究中心副主任;上海杰医创始人
Session 1207 Rare Disease, Unsatisfied Market Demand
www.firstnamelastname.nl
@firstname
David TSUI
Shire公司法规事务区域负责人
Session 1207 Rare Disease, Unsatisfied Market Demand
www.firstnamelastname.nl
@firstname
冯文化
中国医学科学院北京协和医学院药物研究所开发室
Session 1207 Rare Disease, Unsatisfied Market Demand
www.firstnamelastname.nl
@firstname
黄如方
中国罕见病发展中心主任
www.firstnamelastname.nl
@firstname
刘秀凤
Shire公司法规中国区负责人
Session 1208 Panel Discussion
www.firstnamelastname.nl
@firstname
Hae-Young AHN
美国FDA转化医学办公室,临床药理学办公室,临床药理三部副部长
Session 1208 Panel Discussion
www.firstnamelastname.nl
@firstname
刘宏宇
德益阳光生物技术(北京)有限责任公司总裁兼首席执行官
Session 1208 Panel Discussion
www.firstnamelastname.nl
@firstname
吴一龙
广东省肺癌研究所所长;CSCO理事长
Session 1301 Sinyoo Information Technology White Paper Showcase
www.firstnamelastname.nl
@firstname
吴婷
罗氏医学部统计和真实世界研究团队负责人
Session 1301 Sinyoo Information Technology White Paper Showcase
www.firstnamelastname.nl
@firstname
王学兴
新屿信息科技(上海)有限公司 CEO
Session 1301 Sinyoo Information Technology White Paper Showcase
www.firstnamelastname.nl
@firstname
毕红钢
科文斯副总裁兼中国区总经理
Session 1302 Covance White Paper Showcase
www.firstnamelastname.nl
@firstname
Eric LANG
科文斯临床开发战略全球负责人兼副总裁
Session 1302 Covance White Paper Showcase
www.firstnamelastname.nl
@firstname
姜立功
科文斯中国药政事务负责人,高级总监
Session 1302 Covance White Paper Showcase
www.firstnamelastname.nl
@firstname
Bill HANLON
科文斯全球药政事务负责人兼首席研发官
Session 1302 Covance White Paper Showcase
www.firstnamelastname.nl
@firstname
徐列东
科文斯临床研究部中国区负责人
www.firstnamelastname.nl
@firstname
朱铮
科文斯临床研究部中国客户关系管理总监
Session 1302 Covance White Paper Showcase
www.firstnamelastname.nl
@firstname
金迪蒂
副总经理/质控培训总监,北京经纬传奇医药科技有限公司
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
Peter SCHIEMANN
Widler & Schiemann公司管理合伙人
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
叶小平
杭州泰格医药股份有限公司董事长
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
刘海涛
辉瑞(中国)研究开发有限公司质量保证中国策略主管;中国质量保证论坛(CQAF) 现任主席
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
邵颖
上海复星医药(集团)股份有限公司副总裁兼研发中心主任
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
卓永清
RDPAC高级顾问、经纬传奇第三方稽查专业委员会专家、中国医药企业管理协会专家委员会专家
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
范小娜
原北京药监局 GMP专家,经纬传奇第三方稽查专家委员会专家
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
孙家林
副总经理/稽查总监 北京经纬传奇医药科技有限公司
Session 1305 Beijing Jingwei Chuanqi Medicine White Paper Showcase
www.firstnamelastname.nl
@firstname
赵璐
太美医疗科技首席执行官
Session 1306 MobileMD System White Paper Showcase
www.firstnamelastname.nl
@firstname
史煜煌
数据管理部总监
Session 1306 MobileMD System White Paper Showcase
www.firstnamelastname.nl
@firstname
吴问春
太美医疗科技临床研究事业部产品组副总监
Session 1306 MobileMD System White Paper Showcase
www.firstnamelastname.nl
@firstname
杨文颖
DXC科技,生命科学eCTD咨询顾问
Session 1307 CSC White Paper Showcase
www.firstnamelastname.nl
@firstname
姚瑶
DXC科技,生命科学资深培训师
Session 1307 CSC White Paper Showcase
www.firstnamelastname.nl
@firstname
邹莟
DXC科技生物统计实践全球负责人
Session 1307 CSC White Paper Showcase
www.firstnamelastname.nl
@firstname
稻垣孝司
日本参天制药株式会社药品技术开发成熟产品开发总经理
GMP, CMC
www.firstnamelastname.nl
@firstname
孟宪花
勃林格殷格翰(中国)投资有限公司 生物统计科学家
Statistics for Medical Affairs
www.firstnamelastname.nl
@firstname
祁晟
勃林格殷格翰中国 卒中心血管治疗领域负责人
Statistics for Medical Affairs
www.firstnamelastname.nl
@firstname
杨志敏
国家食品药品监督管理总局药品审评中心化药临床一部部长
Opening Plenary Session
www.firstnamelastname.nl
@firstname
陈震
郑州大学教授,亦弘商学院研究员
Session 0102 Where Does China:Stand in the Middle of ICH Updates
www.firstnamelastname.nl
@firstname
陈晓媛
国家食品药品监督管理总局药品审评中心化药临床一部
Session 0106 Consideration and Case Study of Expediting Development and Review of New Drugs
www.firstnamelastname.nl
@firstname
黄清竹
国家食品药品监督管理总局药品审评中心业务管理部
Session 0108 To Accelerate Regulatory Approval of and Patient’s Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice
www.firstnamelastname.nl
@firstname
汪秀琴
江苏省人民医院南京医科大学第一附属医院伦理总监、 伦理委员会副主任委员、科技处副处长
Session 0302 Improving Clinical Study Quality via Multi-collaborations
www.firstnamelastname.nl
@firstname
徐颐
上海观合医药科技有限公司总经理
Session 0306 Responsibilities and Collaborations of Stakeholders in Clinical Research
www.firstnamelastname.nl
@firstname
王骏
国家食品药品监督管理总局药品审评中心统计与临床药理学部 副部长
Session 0502 CDISC/EDC
www.firstnamelastname.nl
@firstname
严平
辉瑞(中国)研究开发有限公司临床统计总监
Session 0505 Quantitative Science and New Regulatory Guidance
www.firstnamelastname.nl
@firstname
朱晓群
罗氏医学科学--肿瘤副总监
Session 0607 Optimizing the Product Life Cycle
www.firstnamelastname.nl
@firstname
王亚宁
Session 0701 Clinical Trial Design of Biosimilar Part I
Session 0702 Clinical Trial Design of Biosimilar Part II
Session 0705 Recent Trends in the Regulation of Biopharmaceutical Products
Session 0707 Pharmacometrics in Early Stage of Clinical Development
www.firstnamelastname.nl
@firstname
陈晓媛
国家食品药品监督管理总局药品审评中心化药临床一部
Session 0701 Clinical Trial Design of Biosimilar Part I
Session 0707 Pharmacometrics in Early Stage of Clinical Development
www.firstnamelastname.nl
@firstname
Nick CECIL
精鼎国际咨询(技术)咨询部副总裁
Session 0701 Clinical Trial Design of Biosimilar Part I
www.firstnamelastname.nl
@firstname
董健
药明生物副总裁,药明生物无锡生产基地负责人, 制药高级工程师
Session 0706 Regulating Biologics under MAH Pilot Program
www.firstnamelastname.nl
@firstname
高晨燕
国家食品药品监督管理总局药品审评中心生物制品临床部部长
Session 0708 Development of Cell Therapy and Regulatory Considerations
www.firstnamelastname.nl
@firstname
马璟
国家上海新药安全评价研究中心主任 上海益诺思生物技术有限公司(InnoStar)董事长
Session 0708 Development of Cell Therapy and Regulatory Considerations
www.firstnamelastname.nl
@firstname
任经天
国家食品药品监督管理总局药品评价中心中药监测与评价处
Session 0802 Established Products/Injectable Products Safety Monitoring and Risk Management
www.firstnamelastname.nl
@firstname
刘巍
国家食品药品监督管理总局药品评价中心业务综合处
Session 0805 How to Improve Safety Communication--Perspectives from Health Authority, Hospital and Industry
www.firstnamelastname.nl
@firstname
倪达文
药明康德临床开发副总裁
Session 1001 New Drug Development by China Domestics R&D Company
Session 1002 Chinese R&D Company Going to Overseas
www.firstnamelastname.nl
@firstname
陈小新
Session 1001 New Drug Development by China Domestics R&D Company
广东众生药业创新药事业部总监
www.firstnamelastname.nl
@firstname
朱正缨
罗欣药业首席医学官
Session 1001 New Drug Development by China Domestics R&D Company
www.firstnamelastname.nl
@firstname
兰炯
扬子江药业集团上海海雁医药科技有限公司总经理
Session 1001 New Drug Development by China Domestics R&D Company
www.firstnamelastname.nl
@firstname
倪达文
药明康德临床开发副总裁
www.firstnamelastname.nl
@firstname
李又欣
绿叶制药高级副总裁
Session 1002 Chinese R&D Company Going to Overseas
www.firstnamelastname.nl
@firstname
涂荣华
人福药业研究院副院长
Session 1002 Chinese R&D Company Going to Overseas
www.firstnamelastname.nl
@firstname
杨大俊
江苏亚盛医药开发有限公司 董事长
Session 1002 Chinese R&D Company Going to Overseas
www.firstnamelastname.nl
@firstname
杨建红
沈阳药科大学亦弘商学院
GMP, CMC
www.firstnamelastname.nl
@firstname
This is a past event
DIA China might have other events you're interested in.
View more events